The prevalence of clinically relevant HPV types and their specific risk for progression and regression in women with atypical squamous cells of uncertain significance (ASCUS) and low-grade squamous intraepithelial lesions (LSIL) were studied in a routine screening population. A 4-year cohort of women (n 5 820) with ASCUS/LSIL and a positive HPV test in triage were followed for 6-9 years. The progression risks for CIN21/CIN31 were determined for single (71.2%) and multiple HPV infections (28.8%). The CIN21 progression risk for all HPV 16, all HPV 35, single HPV 16 and single HPV 35 infections were 65.3% (95% CI: 59.6-71.0), 64.4% (95% CI: 50.4-78.4), 63.8% (95% CI: 56.2-71.4) and 73.7% (95% CI: 53.9-93.5), respectively. Based on CIN21 progression risks four main groups were defined; the HPV 16 group, the HPV 31/33/35 group, the HPV 18/45/51/ 52 group and the HPV 39/56/58/59/66/68 group with progression risks of 65.3% (95% CI: 59.6-71.0), 62.1% (95% CI: 54.8-69.4), 52.6 (95% CI: 45.9-59.3) and 39.5 (95% CI: 33.0-46.0), respectively. In multivariate analyses, women in the age group 40-49 years had an increased risk of CIN21 progression. As for CIN31, HPV 16 had a higher progression risk than other HPV risk groups (p < 0.05). In multiple infections only HPV 16 had a significant additive CIN31 progression risk (p < 0.05) as compared to other HPV risk groups. In summary, HPV types 16 and 35, including the HPV risk group 31/33/35, had a similar CIN21 progression risk, but only HPV 16 had a higher risk for CIN31 progression.
Introduction
Worldwide, cervical cancer is the fourth most common cancer among women. 1 Squamous cell carcinomas account for about 75-80% of the new cervical cancer cases. 2, 3 The disease is due to persistent infection with genital high risk human papillomavirus (hrHPV), 4 normally starting in the transitional zone between the squamous and the columnar epithelium. 5 Most of the hrHPV infections regress spontaneously, whereas 10-15% may progress to high-grade cervical intraepithelial neoplasias (CIN21) and some high-grade lesions further into cancer. 6 It is assumed that it will generally take >10 years from infection until development of cancer. 7 National screening programs have proven useful in lowering the incidence of cervical cancer [8] [9] [10] despite an increasing prevalence of genital hrHPV infections in Western countries. 11 A similar effect has also been observed in Norway. 3 Cervical pre-cancer lesions caused by hrHPV infection can be detected through screening, using cytology or HPV testing. The latter method is more sensitive, but less specific than cytology to detect clinical relevant infections. 12, 13 Similar observations, pertaining to HPV testing, have also been found in delayed triage of ASCUS and LSIL in Norway. [14] [15] [16] Due to the higher sensitivity of HPV testing, several countries, including Norway, are about to implement HPV testing in primary screening. 17 In Norway, >300 women are diagnosed with uterine cervical cancer each year and about 100 women die from the disease. 18 Approximately 4,000 women undergo surgical treatment due to cervical intraepithelial lesion (CIN) grades 2 and 3 (CIN2/3). The Norwegian screening program against cervical cancer is administered by the Cancer Registry of Norway. Until 2015 it was entirely based on microscopy of exfoliated cell (cytology) samples from the uterine cervical region. All women in the age group 25-69 years are invited to participate. Women negative for intraepithelial lesion or malignancy (NILM) are referred every third year. Women with atypical squamous cells of uncertain significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL) have routinely (until 2015) been triaged with HPV testing and repeat cytology after 6-12 months (delayed triage).
The prevalence of HPV types in CIN 2/3 lesions 19, 20 and in cervical cancer 21, 22 has been studied extensively. More recently, also the progression risk of specific HPV types for CIN21 and CIN 31 has been reported. [23] [24] [25] [26] In all these studies HPV 16, along with HPV type 18, 31, 33 and 45 have shown higher risk of CIN21/CIN 31 progression as compared to other HPV types. Similar results have also been reported in a large, population-based cohort of young Danish women. 27, 28 There seems, however, to be a shortage of large studies addressing HPV type specific risk of CIN21 progression and remission in long-term follow-up of ASCUS/LSIL. In our study, we report on HPV type prevalence and HPV type progression risk for CIN21/CIN31 in HPVpositive women in delayed triage of ASCUS/LSIL within a national screening program.
Materials and Methods

Cervical cancer screening
All women in Norway, aged 25-69 years, are eligible for organized cervical screening. During the study period, 2006-2010, women with ASCUS or LSIL were routinely advised a next follow-up with cytology and HPV testing after 6 months.
Definitions
Index sample refers to the initial Pap smear that showed ASCUS or LSIL and led to enrollment in the study. For enrollment the women had to have no abnormal smear and/ or positive HPV test during the previous 2 years period prior to the index (baseline) sample. Progression to CIN21 means progression of a HPV-positive ASCUS/LSIL lesion to cervical intraepithelial lesion grade 2 or worse (CIN21) in a biopsy or in a resected cone specimen. The timespan for progression to CIN21 (or CIN31) was recorded from time of ASCUS/ LSIL at baseline until CIN21 was first detected. The most severe lesion was recorded. All samples were examined as part of routine medical care at the Department of Pathology, Haukeland University Hospital, which is a regional hospital of Western Norway. No pathology reviewing of the cytology or biopsy specimens was performed. A lesion was considered to have undergone remission/regression when (1) HPV testing in clinical follow-up was negative or (2) at least two ensuing cytology and/or cervical biopsy samples with at least 6 months interval were normal and with no HPV positivity registered in the latter period. Moreover, a CIN21 lesion must not occur at any time point during the complete observation period of 6-9 years to warrant a diagnosis of regression. Clinical persistence was annotated for those cases in which the criteria for progression or regression were not fulfilled during 6-9 years of clinical surveillance. A positive HPV test for enrollment in the study refers to the first HPV test taken after index ASCUS/LSIL in cytology. The material for HPV (HCII) testing was taken as a separate cervical brush sample normally in parallel with a sample for a cervical Pap smear. The HPV testing was performed on the Hybrid Capture 2 (HCII) HPV DNA test platform (Qiagen, Gaithersburg, MD) during the whole study period and identified the high risk (hr) HPV types 16, 18, 31, 33, 35, 39, 45 , 51, 52, 56, 58, 59 and 68 without any typing. Information on HPV status was routinely not available for the cytotechnicians. In contrast, HPV status, expressed as HPVpositive or HPV-negative sample, was fully available to all pathologists signing out the cytology report, but with no information available on specific HPV type(s) present in a HPV-positive sample. The samples for HPV testing were collected in specimen transport medium (STM) from Qiagen. Prior to analysis the samples were added denaturation reagent and incubated for 45 min at 658C as described by the manufacturer (Qiagen, Gaithersburg, MD). After sample lysis an aliquot was used for HPV (HCII) testing and the residual material, used for HPV subtyping in our study, was routinely stored at 2208C in Department of Pathology, Haukeland University Hospital.
Study design and inclusion
The study is prospective and population based and includes all women in Western Norway in the period 2006-2010 with an index ASCUS and LSIL sample and a positive HPV test (HC II) in the ensuing follow-up. Women with a lack of clinical follow-up information were also excluded from the study. Based on these criteria 1,262 women were selected from of 201,104 evaluated cytological smears. It should be noted that the outcome of HPV positivity and negativity in the first What's new? While it is known that infection with human papilloma virus (HPV) type 16 can lead to highest-grade cervical intraepithelial neoplasia (CIN31), the HPV types associated with progression to the less dysplastic CIN21 stage are less well studied. Here the authors analyzed data from a national screening program in Norway and found that HPV35, along with HPV31 and 33, was quite common with a CIN21 progression risk similar to HPV16. However, HPV16 had the strongest association with progression to CIN31, underscoring the heterogeneity observed in the CIN21 progression risk group.
control after ASCUS/LSIL has been reported on previously in a partly overlapping cohort (2005-2007) of our study. 29 For the 2006-2007 cohort, covering about half of the women in our study, 410 women (45.9%) tested positive and 484 (54.1%) tested negative at their first follow-up of ASCUS/ LSIL at baseline.
A written consent was required for HPV typing. A letter of invitation to participate in the study (including one reminder) was forwarded to all women yielding 964 written consents (76.4% positive response rate). At the time of study inclusion (year 2012) 38% (n 5 363) of the lesions had progressed to CIN21 and 33% (n 5 322) regressed in the consented group as compared to 37% (n 5 463) and 35% (n 5 447), respectively, for the whole group (n 5 1,262). All consenting women in the 4-year cohort 2006-2009 (n 5 832) were further selected for HPV typing. Prior to the HPV typing analysis all women with a possible insufficient local screening history had their cytology and HPV screening history controlled at the Cancer Registry of Norway. After this latter round of selection, the remaining 820 women (2006) (2007) (2008) (2009) were subjected to HPV typing (Fig. 1) . Of note, all women with persistent abnormal cytology and/or HPV positivity or insufficient clinical records during 6-9 years of clinical follow-up were cross-checked (latest in august 2015) at the Cancer Registry of Norway to ensure that all available screening data had been included for these women. HPV typing. Determination of hrHPV type was done using a commercial multiplex PCR test (f-HPV, Genomed LTD, Middlesex UK) on the bio-banked HCII samples. The f-HPV test identifies the same hrHPV types as in the HCII test and the low risk (lr) HPV types 6 and 11. In short, after isolation of DNA, a multiplex PCR reaction was run with fluorescently labeled HPV type identifying primers and the unique HPV type(s) determined using DNA fragment analysis (ABI model 3130XL,Thermo Fischer, Foster City, CA) as previously described. 30 The Genomed fHPV test participated in the WHO HPV Laboratory Network (LabNet) HPV DNA Proficiency Study, Sweden 2011. The assay correctly identified each of the 46 blinded panel samples and was therefore found to be suitable for detection of the indicated HPV types (Joakim Dillner, MD, WHO HPV LabNet, International HPV, reference Center, Stockholm, Sweden). The f-HPV test results were grouped as single or multiple with respect to hrHPV types present in any given sample. For samples with 
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multiple hrHPV types present, the apparent most dominant HPV type, based on DNA peak height and area in the DNA fragment analysis test, was per definition set as the dominant hrHPV type for a specific sample. Similarly, the presence of multiple hrHPV types in a sample was recorded sequentially from the HPV type with the strongest signal/highest viral load (dominant) to the HPV type with the lowest signal for any given HPV type. For samples, in which no definite HPV type were obtained by the f-HPV test, an alternative HPV test using the Gp51/Gp61 HPV PCR primers and Sanger DNA sequencing was used for hrHPV type identification, as previously reported. 31 The hrHPV DNA type in the latter test was identified using the NCBI BLAST database and regularly >98% sequence homology was recognized for HPV type identity. HrHPV type was determined by the fHPV test in 662 samples (88.0%) and by Sanger sequencing in 90 samples (12.0%).
Statistical analyses
Absolute risk for CIN21/CIN31 progression was determined for overall and for each HPV type as the proportion (%) of women with a specific hrHPV type progressing to CIN21 or CIN31 during the 6-9 years period of observation. These latter calculations were done only in the major cohort (n 5 692) with a defined hrHPV type and with known outcome with respect to progression and remission i.e. women lacking follow-up clinical information (n 5 28) or had persistent disease (n 5 29) were not included. Allocation of an individual HPV type into one of the HPV risk groups was based on its observed specific progression risk to CIN21 as single type infection in our study. In lesions with multiple infections absolute progression risk during 6-9 years of observation was determined between different HPV high risk groups and combinations of those for progression to CIN21 and CIN31. In all these analyses the Pearson's v 2 test was used to evaluate associations between categorical variables. Also, the progression risk of hrHPV-negative women in a similar screening population cohort, 29 were included for comparison. For some parameters mean 6 standard error of the mean (SEM), median and progression risk with 695% confidence intervals (CIs) were determined.
Cumulative CIN21 incidence risks for women positive for (a) HPV 16 or for HPV types belonging to (b) the high risk group (HPV 31, 33 or 35), (c) the intermediate risk group (HPV 18, 45, 51 or 52) or the low risk group (HPV 39, 56, 58, 59, 66 or 68) were calculated using the method described by Kaplan and Meier. 32 In this analysis any women with HPV 16 infection were grouped to the HPV 16 group. Women with HPV 31/33/35 infection(s), as single infection or in combinations, or in combination with other hrHPV types apart from in combination(s) with HPV 16, were allocated to this high risk group. The HPV high risk groups 18/45/51/52 and 39/56/58/ 59/66/68 were defined in a similar manner. Hazard ratios (HRs) with 95% CIs of CIN21 were estimated for groups of hrHPV types using multivariate Cox proportional hazard regression. In the regression model hrHPV risk groups, age and cytology at baseline were included. The data were analyzed using the IBM SPSS statistical package version 22.0 (IBM Corporation, Armonk, NY) and Stata/IC 14.0 software program (StataCorp LP, College Station, TX).
Results
In the study population group and in the hrHPV identified group 456 vs. 412 women were ASCUS positive and similarly 364 vs. 337 women were LSIL positive at baseline in these groups, respectively (Fig. 1) . Of the 820 women in the study population group, 375 (45.7%) had lesions that progressed to CIN21, 286 (34.8%) to CIN31 and 384 (46.8%) lesions regressed. There were 32 women (3.9%) that remained undetermined due to insufficient clinical data and 29 women (3.5%) had persistent disease after 6-9 years of follow-up. Altogether, 47.6% (202) of the women with ASCUS progressed to CIN21 as compared to 51.6% (173) for women with LSIL. As for CIN31, 35.5% (162) of women with ASCUS and 34.1% (124) of women with LSIL progressed. Remission was assessed by (a) HPV-negative test in 174 cases (45.3%), (b) by two negative (normal) cytology and/or biopsy samples in 154 cases (40.1%) or (c) by more than two normal cytology and/or biopsy samples in 56 cases (14.6%) during the study period. Mean (geometrical) age for HPVpositive ASCUS/LSIL lesions that regressed was 34.5 years ((SEM 5 1.9), median 33.5 years) vs. 33.2 years ((SEM 5 0.27), median 32.4 years) for women with lesions that progressed to CIN21. Peak incidence of HPV-positive ASCUS and LSIL at baseline was at age 26 for both lesions that progressed and regressed. A specific hrHPV type, single or multiple, was found in 749 (93.2%) women out of 804 tested for HPV (Fig. 1) .
HPV 16 was the most prevalent HPV type both with respect to CIN21 progression and regression of disease ( Table 1 ). The prevalence of infections with single hrHPV types, two hrHPV types and three or more hrHPV types were 71.2%, 22.4% and 6.5%, respectively (Table 1) . Some hrHPV types, such as HPV 16, 31, 33, 35, 45 and 52, were more common among lesions progressing to CIN21 than undergoing remission (Table 1) . Similarily, hrHPV types 39, 56, 58, 59, 66 and 68 were more common among cases undergoing remission. In two cases lrHPV 6 and in one case lrHPV11 was found.
Because many women had multiple infections, 6-9 years progression risk was studied both for all hrHPV types, dominant hrHPVs and single hrHPV types. The stratification of hrHPV types with respect to progression risks were more discriminative when evaluated as dominant or single hrHPV risk than evaluated as risk for all hrHPV types present (Table  2) . HPV16, 31, 33 and 35 had in particular a high risk of CIN21 progression ( 4 . In further analyses, also the progression risk for CIN31 was determined for all, dominant and single hrHPV types. Overall, the progression risk for CIN31 was higher for HPV 16 than for other HPV types (Table 2) .
Based on the CIN21 progression data from single HPV types the lesions were grouped into four main risk groups, the HPV16 group, the HPV31/ analyses were run for dominant and single HPV type infections in each group. As for CIN31, the HPV 16 progression risk was significantly higher (p < 0.05) than for the other risk HPV groups whether tested for all infections, dominant infections og combinations of single HPV infections in each group (data not shown).
Multiple HPV infections were studied in more detail with respect to CIN21/CIN31 progression risk and HPV risk groups. In these analyses the HPV risk group 31/33/35 had a similar CIN21 progression risk as for HPV 16 (Table 3) . There was some additive CIN21 progression risk in the HPV 31/33/35 group in presence of an HPV 16 infection, although not significant (p 5 0.057). Also, when HPV 16 or HPV 31/33/35 types were present among HPV types in the low risk groups the CIN21 progression risk increased (Table  3) . As for CIN31 progression risk, only HPV 16 infection had a significant additive 6-9 years increased CIN31 progression risk (p < 0.05) as compared to other HPV types and HPV risk groups tested (Table 3) .
Using multivariate Cox regression analysis the various HPV risk groups showed different CIN21 progression risks (Table 4 ). There was a higher CIN21 progression risk among HPV-positive women in the age group between 40 and 49 years of age as compared to women <30 years of age. For the same HPV risk groups 4 years cumulative CIN21 (Fig. 2) .
Discussion
In our study, we have analyzed hrHPV types in HPVpositive samples in delayed triage of ASCUS/LSIL. As a written consent was required to undertake HPV typing, we controlled that the consenting process did not significantly skew the selection of women in the study. The HPV-positive women were followed for a long time period (6-9 years) not only to analyze for progression of disease, but also to establish definite remission of disease based on pre-defined criteria. By the end of the observation period only 3.5% of the recruited women had persistent remaining disease. Thus, in our study hrHPV type-specific risk for progression to CIN21/CIN31 was estimated in the group of women with a 1 The CIN21/CIN31 progression risk of hrHPV-negative women in a screening population cohort 30 similar to our study has been included for comparison.
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Almost two-thirds of women positive for HPV at baseline undergo spontaneous regression within 1 year, 33, 34 so HPVpositive women in delayed triage of ASCUS/LSIL should have a higher CIN21 progression risk than women triaged at baseline. [35] [36] [37] In our study close to half (49.4%) of the HPV-positive women progressed to CIN21. This also implies that hrHPV type and the hrHPV type progression risk, as reported in our study, are skewed towards more aggressive hrHPV types and higher hrHPV progression risks as compared to similar evaluations done among HPV-positive women at baseline. Spontaneous regression and clinical persistence are also known to be different by HPV type, 38 but that was not further addressed in our study.
The risk of progression to CIN21 was determined in the major cohort of women with a defined outcome as progressed (CIN21) or regressed disease. This assumption was considered valid due to the small proportion (3.9%) with clinical persistent disease among women with a specific hrHPV identified. We assumed that the outcome in the latter small group would not significantly affect the HPV type specific risk for CIN21 progression in our study. It was further assumed that the index ASCUS/LSIL in the cytological smears at baseline correlated with the HPV-positive test found in triage of these women. A high CIN21 progression risk among HPV-positive women in our study, as compared to HPV-positive women at baseline 39 would fit with the above assumption. The exact clinical follow-up time of HPVpositive samples could not be estimated with certainty in any individual case, but to obtain a best possible estimate it was ensured that the women were not in clinical follow-up due to previous positive cytology or positive HPV test result(s) prior to inclusion at baseline. Furthermore, the CIN31 progression risk was determined as the proportion of women progressing to CIN 31 as compared to those undergoing remission or only progression to CIN2. It is not known what fraction of the CIN2 lesions that could have progressed further to CIN31 so the HPV type-specific progression risk for CIN31 should be considered a lower estimate of that risk.
HPV 16 is well recognized as the most prevalent HPV type in CIN2/3 lesions 40 as well as in lesions relapsing after primary conization. 41 Also, in our study HPV 16 was the most prevalent hrHPV type in lesions progressing and the HPV type with the highest risk for CIN31 progression. Infections with HPV type 35 were quite common and cervical lesions positive for HPV 35 had a similar CIN21 progression risk as HPV16, but a lower CIN31 progression risk. This was a novel and rather surprising finding in our study. HPV 35 belongs to the a9 subgroup of carcinogenic HPV types, along with HPV 16 and HPV types such as 31, 33, 52, 58 and 67. 42 In the study by Kjaer and coworkers 27 HPV 35 was found in 3.9% of HPV-positive lesions at baseline. Also, in a recent study by Kahng et al. HPV 35 was relatively common in The Republic of Korea and with a relatively high risk of progression. 43 These observations might also have some implications with respect to ongoing vaccine programs and the HPV type coverage within these programs. HPV type 35 Table 3 . The fraction of HPV multiple infections that progressed to CIN21/CIN31 for different groups of hrHPVtypes during 6-9 years of observation after HPV-positive index ASCUS/LSIL in routine cytology. The CIN21/CIN31 progression (%) was analyzed for HPV 16 21 Recently, HPV 35 has also been brought into attention among HPV types others than HPV 16 that may cause oropharyngeal cancer. 44 To our knowledge, the prevalence of HPV35 and its specific risk for progression and remission has not previously been reported in delayed triage of ASCUS/LSIL in a population-based setting within a controlled screening program.
Due to a rather high fraction of multiple infections (29%) CIN21 progression risks were calculated as risk for all types, dominant type and single HPV type present. The rationale for this approach was the assumption that the CIN21 progression risk should be more correctly addressed as single HPV type infection risk. This prediction was also confirmed in the sense that HPV types mainly belonging to the low risk group (HPV 39/56/58/59/66/68) had lower CIN21/CIN31 progression risk when evaluated as single HPV type progression risk than in combination with other HPV types. Regarding CIN31 progression risk, HPV 16 was the dominant HPV type with respect to progression risk among all HPV types tested. The clinical significance of these findings is mainly twofold. First, HPV type matters in terms of progression risk, and second HPV type matters in terms of risk assessment for CIN21 and for CIN31 progression. Concerning clinical management, however, these lesions are routinely treated with cervical cone excision. In a recent publication by Kjaer and coworkers 45 many CIN3 lesions had multiple infections and a high prevalence of infections positive for HPV 16 (Table 2 ). This notion should also be of relevance in view of the high prevalence, especially of HPV 16, but also of HPV 18 and partly HPV 45 detected in cervical cancer as noted by us 30, 41 and others. 19 It is possible that other factors than simple HPV type specific progression risk to CIN21 and CIN31 come into play in terms of progression risk to cervical cancer. One issue that has been raised, based on the high preponderance of HPV 16 and 18 in cervical cancer, has been if some of the high risk lesions located in the endocervical part of cervix uteri could be particular hard to uncover by colposcopy. 19 In summary, we report on HPV type prevalence and CIN21 progression risk in HPV-positive women in triage of ASCUS/LSIL in a population-based cohort of women in routine cervical screening. HPV 16 along with the HPV types 31/33/35 had a similar risk for CIN21 progression. Single HPV infections with HPV 35 and HPV 16 had the highest CIN21 progression risks in our study. HPV 16 was, however, the dominant HPV type with respect to CIN31 progression risk. The findings are consistent with HSIL (CIN2 and CIN3) comprising a rather heterogeneous morphological group of cervical lesions and also with rather different inherent HPV type progression risk profiles. As these lesions have a rather uniform surgical treatment with cone excision, the presence of HPV 16 along with HPV 31/33/35 should in particular caution the clinician of a higher CIN21 progression risk. A sound knowledge of HPV type specific positive (and negative) predictive values for HPV types in low-grade cervical lesions should be important in clinical guidance and decision making as also pointed out by others. 46 
